New Heart Stent Looks Good in Study
Xience V Experimental Drug-Coated Stent May Offer Advantages Over Current Devices
WebMD News Archive
March 27, 2007 (New Orleans) -- An experimental drug-coated heart stent appears to be better at keeping blocked heart arteries open than the current standard, a new study suggests.
In addition, the new stent, known as Xience V, appears to be at least as good as the standard Taxus stent at reducing deaths from heart disease, recurrent heart attacks, and the need for repeat procedures to open blocked heart arteries, says lead researcher Gregg Stone, MD, director of cardiovascular research at Columbia University Medical Center.
"For the patient, this means better long-term outcomes without recurrent heart problems," Stone tells WebMD.
The study was presented at the annual meeting of the American College of Cardiology.
Drug-Coated Stents in Most Cases
Since they were first approved for use in the U.S. in 2003, drug-coated stents have been the rage among cardiologists.
The stents are coated with a polymer that slowly releases a drug to keep scar tissue from forming and reclogging heart arteries after a balloon angioplasty procedure to open them -- a big problem with earlier, bare-metal stents.
Research has shown that these drug-coated stents can reduce the need for repeat procedures to clear clogged arteries and lower the risk of heart attack.
But they’re not perfect. With drug-coated stents, reclogging is less of a problem than with bare-metal stents, but it’s still a problem.
As a result, researchers have been looking for ways to make drug-coated stents safer and more effective, Stone says.
Additionally, recent studies suggest drug-coated stents may carry a delayed risk of dangerous blood clots.
The new study, designed before the blood clot risks were well known, did not address the issue of which stent was better in that regard.
But the experimental stent has other advantages, Stone says.
Stent May Promote Faster Healing
Its very thin metal base is coated with a powerful drug called everolimus to discourage scar tissue. Everolimus is not approved for use in the U.S.
The polymer used to deliver the drug is very thin, nonadhesive, and nonsticky, so it may promote faster healing of the blood vessel walls.